근육 경련 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 약물 유형별, 투여 경로별, 유통 채널별, 지역별, 시장 경쟁별(2020-2030년)
Muscle Spasticity Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Route of Administration, By Distribution Channel, By Region and Competition, 2020-2030F
상품코드:1703335
리서치사:TechSci Research
발행일:2025년 04월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
근육 경련 세계 시장 규모는 2024년 41억 1,000만 달러로 평가되었고, 예측 기간 동안 55억 3,000만 달러, 2030년까지 5.03%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다.
세계 근경련 시장은 광범위한 헬스케어 산업에서 역동적으로 진화하고 있는 분야로, 근경련의 복잡한 병태생리에 대처하는 데 초점을 맞추었습니다. 근경련은 비자발적인 근육 수축과 경직이 특징이며, 다발성 경화증, 뇌성마비, 척수 손상과 같은 신경 질환에 기인하는 경우가 많습니다. 이 시장은 신경질환의 유병률 증가, 의료기술의 발전, 고령화 인구 증가 등을 배경으로 수년 동안 큰 성장과 기술 혁신을 이루었습니다.
Global Muscle Spasticity Market was valued at USD 4.11 Billion in 2024 and is expected to reach USD 5.53 Billion in the forecast period with a CAGR of 5.03% through 2030. The global muscle spasticity market is a dynamic and evolving sector within the broader healthcare industry, focused on addressing the complex medical condition of muscle spasticity. Muscle spasticity is characterized by involuntary muscle contractions and stiffness, often resulting from neurological disorders such as multiple sclerosis, cerebral palsy, or spinal cord injuries. This market has witnessed significant growth and innovation over the years, driven by the increasing prevalence of neurological disorders, advancements in medical technology, and a growing aging population.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 4.11 Billion
Market Size 2030
USD 5.53 Billion
CAGR 2025-2030
5.03%
Fastest Growing Segment
Online Pharmacies
Largest Market
North America
Key Market Drivers
Rising Incidence of Neurological Disorders
The rising incidence of neurological disorders is a pivotal driver behind the burgeoning growth of the global muscle spasticity market. Neurological conditions such as multiple sclerosis (MS), cerebral palsy, spinal cord injuries, stroke, and Parkinson's disease frequently manifest with muscle spasticity, characterized by involuntary muscle contractions and stiffness that significantly impair patients' quality of life.
Multiple sclerosis, in particular, has seen a notable increase in prevalence. According to the World Health Organization (WHO), over 1.8 million people worldwide are affected by MS, with a higher incidence among young adults and females. This autoimmune disease affects the central nervous system and is a leading contributor to muscle spasticity. As the number of MS cases continues to rise, so does the demand for effective treatments to alleviate the debilitating symptoms associated with the condition. Pharmaceutical companies have responded by developing a range of medications aimed at providing relief and improving the daily lives of patients.
Key Market Challenges
High Treatment Costs
High treatment costs pose a significant hurdle in the global muscle spasticity market, impeding the accessibility of care for individuals grappling with this debilitating condition. Muscle spasticity, characterized by involuntary muscle contractions and stiffness, often results from neurological disorders like multiple sclerosis, cerebral palsy, and spinal cord injuries. While treatment options have advanced, the soaring expenses associated with these therapies present a considerable challenge for both patients and healthcare systems. One of the primary issues driving the high treatment costs is the development and production of specialized medications and medical devices tailored for muscle spasticity management. Pharmaceutical companies invest heavily in research and development to create effective drugs that target the condition's symptoms and underlying causes. These innovative treatments, while offering hope for improved patient outcomes, often come with a substantial price tag, making them financially burdensome for many patients.
Key Market Trends
Increasing Awareness and Education
Increasing awareness and education have become instrumental in propelling the global muscle spasticity market forward. In recent years, concerted efforts by advocacy groups, healthcare organizations, and pharmaceutical companies have led to a significant uptick in public understanding and recognition of this debilitating condition. Muscle spasticity, a common symptom in neurological disorders like multiple sclerosis, spinal cord injuries, and stroke, was often overlooked or misunderstood in the past. However, with increased awareness campaigns and educational initiatives, both patients and healthcare providers are now more informed about its prevalence, symptoms, and available treatment options.
Key Market Players
Ipsen Pharma
Allergan
Acorda Therapeutics, Inc.
Merz Pharma
Novartis AG
Beximco Pharmaceuticals Ltd.
Zydus Cadila
Porex Corporation
Teva Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd
Report Scope:
In this report, the Global Muscle Spasticity Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Muscle Spasticity Market, By Drug Type:
Baclofen
Botulinum Toxin
Diazepam
Dantrolene Sodium
Others
Muscle Spasticity Market, By Route of Administration:
Oral
Intramuscular
Others
Muscle Spasticity Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Muscle Spasticity Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Muscle Spasticity Market.
Available Customizations:
Global Muscle Spasticity Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Global Muscle Spasticity Market Outlook
4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By Drug Type (Baclofen, Botulinum Toxin, Diazepam, Dantrolene Sodium, Others)
4.2.2. By Route of Administration (Oral, Intramuscular, Others)
4.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
4.2.4. By Region
4.2.5. By Company (2024)
4.3. Market Map
4.3.1. By Drug Type
4.3.2. By Route of Administration
4.3.3. By Distribution Channel
4.3.4. By Region
5. Asia Pacific Muscle Spasticity Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Type
5.2.2. By Route of Administration
5.2.3. By Distribution Channel
5.2.4. By Country
5.3. Asia Pacific: Country Analysis
5.3.1. China Muscle Spasticity Market Outlook
5.3.1.1. Market Size & Forecast
5.3.1.1.1. By Value
5.3.1.2. Market Share & Forecast
5.3.1.2.1. By Drug Type
5.3.1.2.2. By Route of Administration
5.3.1.2.3. By Distribution Channel
5.3.2. India Muscle Spasticity Market Outlook
5.3.2.1. Market Size & Forecast
5.3.2.1.1. By Value
5.3.2.2. Market Share & Forecast
5.3.2.2.1. By Drug Type
5.3.2.2.2. By Route of Administration
5.3.2.2.3. By Distribution Channel
5.3.3. Australia Muscle Spasticity Market Outlook
5.3.3.1. Market Size & Forecast
5.3.3.1.1. By Value
5.3.3.2. Market Share & Forecast
5.3.3.2.1. By Drug Type
5.3.3.2.2. By Route of Administration
5.3.3.2.3. By Distribution Channel
5.3.4. Japan Muscle Spasticity Market Outlook
5.3.4.1. Market Size & Forecast
5.3.4.1.1. By Value
5.3.4.2. Market Share & Forecast
5.3.4.2.1. By Drug Type
5.3.4.2.2. By Route of Administration
5.3.4.2.3. By Distribution Channel
5.3.5. South Korea Muscle Spasticity Market Outlook
5.3.5.1. Market Size & Forecast
5.3.5.1.1. By Value
5.3.5.2. Market Share & Forecast
5.3.5.2.1. By Drug Type
5.3.5.2.2. By Route of Administration
5.3.5.2.3. By Distribution Channel
6. Europe Muscle Spasticity Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Type
6.2.2. By Route of Administration
6.2.3. By Distribution Channel
6.2.4. By Country
6.3. Europe: Country Analysis
6.3.1. France Muscle Spasticity Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Type
6.3.1.2.2. By Route of Administration
6.3.1.2.3. By Distribution Channel
6.3.2. Germany Muscle Spasticity Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Type
6.3.2.2.2. By Route of Administration
6.3.2.2.3. By Distribution Channel
6.3.3. Spain Muscle Spasticity Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Type
6.3.3.2.2. By Route of Administration
6.3.3.2.3. By Distribution Channel
6.3.4. Italy Muscle Spasticity Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Drug Type
6.3.4.2.2. By Route of Administration
6.3.4.2.3. By Distribution Channel
6.3.5. United Kingdom Muscle Spasticity Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Drug Type
6.3.5.2.2. By Route of Administration
6.3.5.2.3. By Distribution Channel
7. North America Muscle Spasticity Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Type
7.2.2. By Route of Administration
7.2.3. By Distribution Channel
7.2.4. By Country
7.3. North America: Country Analysis
7.3.1. United States Muscle Spasticity Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Type
7.3.1.2.2. By Route of Administration
7.3.1.2.3. By Distribution Channel
7.3.2. Mexico Muscle Spasticity Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Type
7.3.2.2.2. By Route of Administration
7.3.2.2.3. By Distribution Channel
7.3.3. Canada Muscle Spasticity Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Type
7.3.3.2.2. By Route of Administration
7.3.3.2.3. By Distribution Channel
8. South America Muscle Spasticity Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Type
8.2.2. By Route of Administration
8.2.3. By Distribution Channel
8.2.4. By Country
8.3. South America: Country Analysis
8.3.1. Brazil Muscle Spasticity Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Type
8.3.1.2.2. By Route of Administration
8.3.1.2.3. By Distribution Channel
8.3.2. Argentina Muscle Spasticity Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Type
8.3.2.2.2. By Route of Administration
8.3.2.2.3. By Distribution Channel
8.3.3. Colombia Muscle Spasticity Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Type
8.3.3.2.2. By Route of Administration
8.3.3.2.3. By Distribution Channel
9. Middle East and Africa Muscle Spasticity Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Type
9.2.2. By Route of Administration
9.2.3. By Distribution Channel
9.2.4. By Country
9.3. MEA: Country Analysis
9.3.1. South Africa Muscle Spasticity Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Type
9.3.1.2.2. By Route of Administration
9.3.1.2.3. By Distribution Channel
9.3.2. Saudi Arabia Muscle Spasticity Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Type
9.3.2.2.2. By Route of Administration
9.3.2.2.3. By Distribution Channel
9.3.3. UAE Muscle Spasticity Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Type
9.3.3.2.2. By Route of Administration
9.3.3.2.3. By Distribution Channel
10. Market Dynamics
10.1. Drivers
10.2. Challenges
11. Market Trends & Developments
11.1. Recent Developments
11.2. Product Launches
11.3. Mergers & Acquisitions
12. Global Muscle Spasticity Market: SWOT Analysis
